Skip to main content
italianoIT
European Commission logo print header

Regenerative treatment of complete Traumatic Spinal Cord injury with a surgical implantation of a biodegradable device with FGF1 and nerve grafts

Obiettivo

Today there is no regenerative therapy available for treatment of complete spinal cord injuries (SCI). BioArctic Neuroscience develops a novel treatment of complete SCI. The method is based on the regeneration of functional nerves in the injured spinal cord. Nerve grafts are transplanted into the injured spinal cord, by using a biodegradable device, loaded with a growth factor and nerve grafts (these three components are abbreviated SC0806). Efficacy and safety of the treatment has been demonstrated in an in vivo model of SCI. The therapy has been designated Orphan Drug status in Europe and in USA. Ethical approval to commence into clinical trial in Sweden was recently granted.
The proposed project is the first clinical trial of the treatment of complete spinal cord injury. Following surgery at the Karolinska University Hospital, patients will receive rehabilitation in their home countries, with state of the art robotics equipment, at clinics in Denmark, Finland and Sweden.

This clinical study will be the first in-human trial with this new treatment concept. Several interim analyses are included in the study design to secure the safety of the patients. This is a single dose study in up to 3 sequences (A, B and C) in 27 subjects with complete traumatic SCI. In the first sequence (A), 6 subjects will be randomized to a surgical procedure where SC0806 will be implanted at the spinal cord, and receive robotics assisted walking training for 18 months, and 3 subjects will be randomized to specific walking training only. For safety reasons, the first three subjects will be operated on and implanted with at least 1 month in between. If efficacy is demonstrated, control subjects from (A) and (B) and (C) will later be given the opportunity to receive treatment with SC0806.The proposed project spans a period of 42 months and will start nov 2014 with screening, inclusion and treatment of patients in Sweden.

Campo scientifico

Programma(i)

Argomento(i)

Invito a presentare proposte

H2020-PHC-2014-2015

Vedi altri progetti per questo bando

Bando secondario

H2020-PHC-2014-single-stage

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

BIOARCTIC AB
Contribution nette de l'UE
€ 652 987,00
Indirizzo
Warfvinges vag 35
112 51 Stockholm
Svezia

Mostra sulla mappa
PMI

L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.
Sì
Regione
Östra Sverige Stockholm Stockholms län
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Altri finanziamenti
€ 6 148 311,50

Partecipanti (7)

Condividi questa pagina

Scarica

Ultimo aggiornamento: 17 Agosto 2022

Il mio booklet

Permalink: https://cordis.europa.eu/project/id/643853/it

European Union, 2023